Novel Compounds and Drugs and Related Patents in Lung Cancer Chemotherapy

Lung cancer affecting the majority of patients is usually present with advanced stage and contributes in killing more people than any other malignancy in the world. The discovery of a number of lung cancer-molecular alterations contributes to uniquely targeted therapies with specific inhibitors for non-small cell lung cancer such as erlotinib, gefitinib and crizotinib.

Pemetrexed has statistically shown significantly reduced adverse-side effects of drug compared with docetaxel. V1801, an analog of gefitinib may overcome gefitinib resistance in patients with non-small cell lung cancer. Thymosin α1, an immunomodulator, significantly improves patient’s quality of life by enhancing T-cell function, stimulation of T-cell maturation and differentiation. Various novel compounds and chemotherapeutics were introduced in 2013 patents such as taxane, quinazoline, arylamino purine, benzodiazepine, pyrrolopyrimidine, nitrobenza-mide, cyclopropane amide, 4-iodo-3-nitrobenzamide, heteroaryl (alkyl) dithiocarba-mate, and histone deacetylase in treating non-small-cell lung cancer and piperidine, piperazine, picoplatin, and arsenic trioxide in treating small-cell lung cancer. Currently, new drugs such as alectinib, AP26113, crizotinib, etc. are in the pipeline.

Keywords: ALK, BRACA1, cancer, carboplatin, chemotherapy, compounds, docetaxel, drugs, EGFR-TKI, ERCC1, erotinib, FANCD2, KRAS, lung, pemetrexed, platinum-based, RAD51, related patents, SMO, VEGF.